Clarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015

There has been a lot of discussion about the Progressive Disease (PD) number reported in an erroneous slide deck that was inadvertently uploaded on Monday, 25 May 2015, to the website of the Market Observation Post System (MOPS) at the Taipei Exchange (GreTai Securities Market). OBI Pharma (OBI) directly and thoroughly addressed this matter at […]

HOMEWhat’s NewNewsClarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2014.Dec.08

Cancer Active Immunotherapy OBI-822 Mechanism Action

2015.Aug.31

OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016